Zobrazeno 1 - 10
of 479
pro vyhledávání: '"Allan, Lipton"'
Autor:
Luis Costa, Rakesh Kumar, Cynthia Villarreal-Garza, Saket Sinha, Sunil Saini, Jayanti Semwal, Vartika Saxsena, Vaishali Zamre, Chintamani Chintamani, Mukurdipi Ray, Chikako Shimizu, Lejla Hadzikadic Gusic, Masakazu Toi, Allan Lipton
Publikováno v:
Breast, Vol 73, Iss , Pp 103623- (2024)
Despite advances in breast cancer care, breast cancer in young women (BCYW) faces unique challenges, diagnostic delays, and limited awareness in many countries. Here, we discuss the challenges and consequences associated with the delayed diagnosis of
Externí odkaz:
https://doaj.org/article/fbe7ddde39ee443ea4883eaf74001fb2
Autor:
Benoit Cadieux, Robert Coleman, Pegah Jafarinasabian, Allan Lipton, Robert Z. Orlowski, Fred Saad, Giorgio V. Scagliotti, Kazuyuki Shimizu, Alison Stopeck
Publikováno v:
Journal of Bone Oncology, Vol 33, Iss , Pp 100416- (2022)
Skeletal-related events (SREs) are complications of bone metastases and carry a significant patient and economic burden. Denosumab is a receptor activator of nuclear factor-κB ligand (RANKL) inhibitor approved for SRE prevention in patients with mul
Externí odkaz:
https://doaj.org/article/0e7638b19e4e4d76af625c7c7fd00821
Autor:
Bijesh George, P. Mukundan Pillai, Aswathy Mary Paul, Revikumar Amjesh, Kim Leitzel, Suhail M. Ali, Oleta Sandiford, Allan Lipton, Pranela Rameshwar, Gabriel N. Hortobagyi, Madhavan Radhakrishna Pillai, Rakesh Kumar
Publikováno v:
Cells, Vol 10, Iss 2, p 433 (2021)
To define the growing significance of cellular targets and/or effectors of cancer drugs, we examined the fitness dependency of cellular targets and effectors of cancer drug targets across human cancer cells from 19 cancer types. We observed that the
Externí odkaz:
https://doaj.org/article/d6c4e6dac85a4706bdd630f119086ed9
Autor:
Douglas J. Warner, Li Zhu, Andrew Spencer, Fred Saad, Neal D. Shore, Janet E. Brown, David Henry, Alison T. Stopeck, Karim Fizazi, Matthew R. Smith, Allan Lipton
Conflict of Interest Form
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8f9480ac81ceb948c6c3f43c289b3a1
https://doi.org/10.1158/1078-0432.22465662.v1
https://doi.org/10.1158/1078-0432.22465662.v1
Autor:
Douglas J. Warner, Li Zhu, Andrew Spencer, Fred Saad, Neal D. Shore, Janet E. Brown, David Henry, Alison T. Stopeck, Karim Fizazi, Matthew R. Smith, Allan Lipton
Supplementary Figure S1: Combined patient population and treatments in the three phase III studies included in the analysis. Supplementary Figure S2: OS (A), DP (B), and DPB (C) stratified by category ({greater than or equal to} or < median) of month
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4aa395393d5f57fb09199aa38af2e239
https://doi.org/10.1158/1078-0432.22465659.v1
https://doi.org/10.1158/1078-0432.22465659.v1
Autor:
Allan Lipton, John Winslow, Gordon Parry, Michael Bates, Wolfgang J. Köstler, Christian F. Singer, Eva-Maria Fuchs, Suhail M. Ali, Jodi Weidler, Kim Leitzel, Weidong Huang, Gundo Diedrich, Anasuya Saha, Elicia Penuel, Jayee Banerjee, Xueguang Jin, Jeff Sperinde
Purpose: p95HER2 is an NH2-terminally truncated form of HER2 that lacks the trastuzumab binding site and is therefore thought to confer resistance to trastuzumab treatment. In this report, we introduce a new antibody that has enabled the first direct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08f29e06eab1b21289296b5307d3c685
https://doi.org/10.1158/1078-0432.c.6519126
https://doi.org/10.1158/1078-0432.c.6519126
Autor:
Allan Lipton, John Winslow, Gordon Parry, Michael Bates, Wolfgang J. Köstler, Christian F. Singer, Eva-Maria Fuchs, Suhail M. Ali, Jodi Weidler, Kim Leitzel, Weidong Huang, Gundo Diedrich, Anasuya Saha, Elicia Penuel, Jayee Banerjee, Xueguang Jin, Jeff Sperinde
CCR Translation for This Article from Quantitation of p95HER2 in Paraffin Sections by Using a p95-Specific Antibody and Correlation with Outcome in a Cohort of Trastuzumab-Treated Breast Cancer Patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21498d51ffd5751c6c06e68e1e265a98
https://doi.org/10.1158/1078-0432.22442391
https://doi.org/10.1158/1078-0432.22442391
Autor:
Douglas J. Warner, Li Zhu, Andrew Spencer, Fred Saad, Neal D. Shore, Janet E. Brown, David Henry, Alison T. Stopeck, Karim Fizazi, Matthew R. Smith, Allan Lipton
Purpose: Bone antiresorptive agents can significantly reduce bone turnover markers (BTM) in patients with advanced cancer. We evaluated association of changes in BTMs with overall survival (OS), disease progression (DP), and disease progression in bo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29d21f8a02c93f5b24160e30d1275e9d
https://doi.org/10.1158/1078-0432.c.6526101.v1
https://doi.org/10.1158/1078-0432.c.6526101.v1
Autor:
Carlos L. Arteaga, Michael Bates, Allan Lipton, Wolfgang J. Kostler, Kim Leitzel, Ali Mukherjee, Sailaja Pidaparthi, Rajiv Dua, Jeff Sperinde, John Winslow, Elicia Penuel, Gordon B. Mills, Ana María González-Angulo, Justin M. Balko, Anindita Chakrabarty, Shuying Liu, Shizhen Emily Wang, Archana Narasanna, Ritwik Ghosh
Supplementary Figure Legends 1-5 from Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76fbf72fe0e25818c4e68211404ff25b
https://doi.org/10.1158/0008-5472.22388676.v1
https://doi.org/10.1158/0008-5472.22388676.v1
Autor:
Carlos L. Arteaga, Michael Bates, Allan Lipton, Wolfgang J. Kostler, Kim Leitzel, Ali Mukherjee, Sailaja Pidaparthi, Rajiv Dua, Jeff Sperinde, John Winslow, Elicia Penuel, Gordon B. Mills, Ana María González-Angulo, Justin M. Balko, Anindita Chakrabarty, Shuying Liu, Shizhen Emily Wang, Archana Narasanna, Ritwik Ghosh
Supplementary Figure 3 from Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::441f129dfef037b56d4ac8701219193c
https://doi.org/10.1158/0008-5472.22388685.v1
https://doi.org/10.1158/0008-5472.22388685.v1